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Recently, Anne-Sophie Heimes and col-
leagues from the University Hospital of 
Mainz published a study to gain a better un-
derstanding of the association of specific im-
mune responses with prognosis in breast can-
cer (Heimes et al., 2017). Although it is well 
established that tumor-infiltrating lympho-
cytes have prognostic and predictive impact, 
the specific role of individual cell types is still 
discussed controversially (Schumacher and 
Schreiber, 2015; Denkert et al., 2010; Salgado 
et al., 2015; Iglesia et al., 2016; Rody et al., 
2009; Mahmoud et al., 2011). To gain a 
deeper understanding, 197 node-negative 
breast carcinomas of patients not treated with 
adjuvant therapy were analyzed for T-cell and 
B-cell markers based on gene-expression data 
by immunostaining (Heimes et al., 2017). 
Moreover, two immune checkpoint markers, 
PD-1 and CTLA-4, were analyzed. In a mul-
tivariate analysis, infiltration of both T-cells 
and B-cells was significantly associated with 
better prognosis. Also the immune checkpoint 
markers showed a significant association with 
prognosis, independent of the clinical-patho-
logical variables. Particularly interesting re-
sults were obtained after analysis of the mo-
lecular subtypes HER2+, basal-like (ER-/ 
HER2-), luminal A (ER+, HER2-, AURKA-
low) and luminal B (ER+, HER2-, AURKA-
high). The prognostic effect of immune cells 
(T- and B-cells) was strongest in the HER2+ 
molecular subtype. Major differences were 
obtained between the other molecular sub-
types with T-cells most pronounced in the lu-
minal A, B-cells in the luminal B and the im-
mune regulators in basal-like carcinomas. 
The positive prognostic influence of lym-
phocytic infiltrates has been known for dec-
ades (Di Paola et al., 1974; Aaltomaa et al., 
1992). While the relevance of T-cells has 
been accepted since long, the key prognostic 
impact of the humoral immune system has 
only been reported in 2008 (Schmidt et al., 
2008) and the prognostic role of individual 
cell types and related factor of influence have 
been further assessed in several studies 
(Heimes et al., 2017; Schmidt et al., 2018, 
2012; Mattsson et al., 2015; Sicking et al., 
2014). The situation remains challenging, 
since only the presence of T- and B-cells in 
tumor tissue does not seem to be sufficient to 
guarantee a favorable prognostic influence. 
Besides lymphocyte infiltration, further fac-
tors seem to be relevant, including the redox 
status, migration capacity, proliferation and 
the metabolic microenvironment (Hammad et 
al., 2016; Cadenas et al., 2010, 2014; Mar-
chan et al., 2017; Hassan et al., 2017; Hellwig 
et al., 2016; Stock et al., 2015; Stewart et al., 
2012). A particularly critical aspect is to con-
sider negative immune regulators, such as 
CTLA-4 and PD-1. In conclusion, the study 
of Heimes and colleagues (2017) clearly 
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shows that the analysis of tumor infiltrating 
lymphocytes should at least include differen-
tiation between T-cells, B-cells/plasma cells 
and negative immune regulators, and should 
independently consider the four molecular 
subtypes HER2+, basal-like, luminal A and 
luminal B. 
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